Arrowhead Launches First Commercial Drug, Eyes sHTG Expansion

Ticker: ARWR · Form: 10-K · Filed: Nov 25, 2025 · CIK: 879407

Sentiment: bullish

Topics: RNAi Therapeutics, Rare Disease, Cardiovascular Disease, Drug Development, Biotechnology, FDA Approval, Commercial Launch

Related Tickers: ARWR, ALNY, SRPT, AMGN, TAK, GSK, NVS

TL;DR

**ARWR's REDEMPLO launch is a game-changer, signaling a bullish shift from R&D to commercialization with significant upside if sHTG approval follows.**

AI Summary

Arrowhead Pharmaceuticals, Inc. (ARWR) achieved a significant milestone in 2025 with the FDA approval and commercial launch of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS), marking its first commercial product. The company is actively pursuing a supplemental NDA for REDEMPLO in severe hypertriglyceridemia (sHTG) in 2026, with Phase 3 studies (SHASTA-3, SHASTA-4, SHASTA-5) fully enrolled. ARWR reported an approximate market value of $1.4 billion for its non-affiliate common stock as of March 31, 2025. The company maintains a robust pipeline with 18 drug candidates in clinical trials, ranging from Phase 1 to Phase 3, leveraging its proprietary TRiM platform for tissue-specific RNAi delivery. Strategic partnerships with companies like Sarepta Therapeutics, Inc. and Amgen Inc. provide non-dilutive capital, supporting REDEMPLO and other wholly-owned programs. Key pipeline assets include Zodasiran (ARO-ANG3) in Phase 3 for Homozygous Familial Hypercholesterolemia (HoFH) and ARO-DIMER-PA, a dual-functional RNAi molecule targeting PCSK9 and APOC3, entering Phase 1/2a for Mixed Hyperlipidemia.

Why It Matters

Arrowhead's successful FDA approval and launch of REDEMPLO for FCS is a critical validation of its RNAi platform, shifting the company from a pure R&D play to a commercial entity. This move could significantly impact investors by providing a new revenue stream and reducing reliance on milestone payments from partners, potentially boosting ARWR's valuation in the competitive biotech landscape. For patients with rare diseases like FCS, REDEMPLO offers a novel treatment option, while the planned sHTG expansion could address a broader market, challenging existing lipid-lowering therapies. The company's ability to execute on its commercial strategy and advance its deep pipeline, including the innovative dual-target ARO-DIMER-PA, will be key to its long-term market position against rivals like Alnylam Pharmaceuticals.

Risk Assessment

Risk Level: medium — The company has transitioned to commercialization with REDEMPLO, but its financial success is heavily dependent on market adoption and the approval of additional indications like sHTG in 2026. While ARWR has 18 drug candidates in clinical trials, the inherent risks of drug development, including potential trial failures or regulatory setbacks, remain substantial, as highlighted by the ongoing Phase 3 studies for sHTG.

Analyst Insight

Investors should monitor REDEMPLO's commercial uptake and the progress of the sHTG supplemental NDA filing in 2026. Given the recent commercial launch and deep pipeline, consider ARWR as a growth-oriented biotech with significant potential, but be aware of the inherent risks associated with clinical development and market penetration in the pharmaceutical sector.

Key Numbers

$1.4 billion — Market Value of Non-Affiliate Common Stock (As of March 31, 2025, indicating significant market capitalization.)
18 — Drug Candidates in Clinical Trials (Demonstrates a robust and diverse pipeline from Phase 1 to Phase 3.)
2025 — Year of First Commercial Launch (Marks the FDA approval and commercialization of REDEMPLO.)
2026 — Planned Supplemental NDA Filing Year (For REDEMPLO in severe hypertriglyceridemia (sHTG), pending Phase 3 success.)
7 — Cell Types Targeted by TRiM Platform (Highlights the versatility and broad applicability of their RNAi delivery technology.)

Key Players & Entities

ARROWHEAD PHARMACEUTICALS, INC. (company) — registrant
ARWR (company) — ticker symbol
REDEMPLO (company) — first FDA-approved commercial product
U.S. Food and Drug Administration (regulator) — approved REDEMPLO
Sarepta Therapeutics, Inc. (company) — license and collaboration partner
Amgen Inc. (company) — license and collaboration partner
Takeda Pharmaceutical Company Limited (company) — license and collaboration partner
Glaxosmithkline Intellectual Property (No. 3) Limited (company) — license and collaboration partner
Novartis Pharma AG (company) — license and collaboration partner
$1.4 billion (dollar_amount) — aggregate market value of common stock held by non-affiliates as of March 31, 2025

FAQ

What is Arrowhead Pharmaceuticals' first commercial product?

Arrowhead Pharmaceuticals' first commercial product is REDEMPLO (plozasiran), which received U.S. Food and Drug Administration (FDA) approval in 2025 as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome (FCS). This marks a significant transition for the company into commercial operations.

What is the strategic outlook for REDEMPLO beyond Familial Chylomicronemia Syndrome?

Beyond FCS, Arrowhead Pharmaceuticals plans to file a supplemental New Drug Application (NDA) for REDEMPLO in severe hypertriglyceridemia (sHTG) in 2026, pending successful completion of Phase 3 clinical studies (SHASTA-3, SHASTA-4, SHASTA-5). The company intends to expand its commercial capabilities to support marketing in sHTG, a higher prevalence disease.

How does Arrowhead Pharmaceuticals' TRiM platform work?

Arrowhead Pharmaceuticals' Targeted RNAi Molecule (TRiM) platform utilizes ligand-mediated delivery to enable tissue-specific targeting of RNAi therapeutics. It is designed to be structurally simple, comprising a potent RNA trigger, a high-affinity targeting ligand, various linker chemistries, and structures that enhance pharmacokinetics, allowing for the silencing of disease-associated genes.

What are the key risks for Arrowhead Pharmaceuticals investors?

Key risks for Arrowhead Pharmaceuticals investors include the inherent uncertainties of clinical trial outcomes, regulatory approvals for pipeline candidates like those for sHTG, and the commercial success of REDEMPLO in a competitive market. The company's ability to effectively scale its commercial organization for broader indications also presents a risk.

Which major pharmaceutical companies has Arrowhead Pharmaceuticals partnered with?

Arrowhead Pharmaceuticals has entered into multiple license and collaboration agreements with leading biotech and pharmaceutical companies, including Sarepta Therapeutics, Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Glaxosmithkline Intellectual Property (No. 3) Limited, and Novartis Pharma AG. These partnerships aim to expand the reach of its technology and provide non-dilutive capital.

What is ARO-DIMER-PA and its significance for Arrowhead Pharmaceuticals?

ARO-DIMER-PA is a dual-functional RNAi molecule developed by Arrowhead Pharmaceuticals designed to simultaneously silence the expression of the PCSK9 and APOC3 genes in hepatocytes for Mixed Hyperlipidemia. This represents an important advancement for the RNAi field as it is the first clinical candidate to target two genes simultaneously in one molecule, enabled by Arrowhead's TRiM platform, and is entering a Phase 1/2a clinical trial.

What is the market value of Arrowhead Pharmaceuticals' common stock?

As of March 31, 2025, the aggregate market value of Arrowhead Pharmaceuticals' voting and non-voting outstanding common stock held by non-affiliates was approximately $1.4 billion, based upon the closing stock price of its common stock.

How many drug candidates does Arrowhead Pharmaceuticals have in clinical trials?

Arrowhead Pharmaceuticals currently has 18 discovered drug candidates in clinical trials, spanning from early-stage (Phase 1) to late-stage (Phase 3). This extensive pipeline demonstrates the company's commitment to developing a broad range of RNAi-based therapies for various intractable diseases.

What is the mechanism of action for Arrowhead Pharmaceuticals' RNAi therapeutics?

Arrowhead Pharmaceuticals' RNAi therapeutics leverage the natural RNA interference mechanism in living cells. Double-stranded RNAi triggers (siRNAs) are introduced, loaded into the RNA-induced silencing complex (RISC), and then degrade complementary messenger RNAs (mRNA), thereby stopping the production of specific disease-causing proteins. This catalytic process results in a relatively long duration of effect.

What is Arrowhead Pharmaceuticals' approach to expanding RNAi delivery beyond the liver?

Arrowhead Pharmaceuticals is leading the expansion of RNAi delivery beyond the liver using its TRiM platform. This platform has demonstrated the potential to reach multiple tissues throughout the body, currently enabling delivery of siRNA to seven different cell types, which is crucial for addressing a wider range of diseases not confined to hepatic targets.

Risk Factors

FDA Approval and Commercialization Risks [high — regulatory]: The company's success is heavily reliant on FDA approvals for its drug candidates, including REDEMPLO for severe hypertriglyceridemia (sHTG) in 2026. Delays or failures in the approval process, or challenges in commercializing approved products like REDEMPLO, could significantly impact revenue and market position.
Competition and Market Adoption [medium — market]: Arrowhead faces competition from established pharmaceutical companies and other RNAi developers. The market adoption of REDEMPLO and future pipeline candidates will depend on demonstrating clear clinical benefits, safety profiles, and cost-effectiveness compared to existing treatments.
Pipeline Development and Clinical Trial Success [high — operational]: With 18 drug candidates in clinical trials, the company faces inherent risks in drug development, including the possibility of clinical trial failures due to efficacy or safety issues. The success of its TRiM platform in delivering therapies to specific tissues is critical for all pipeline assets.
Reliance on Partnerships and Non-Dilutive Capital [medium — financial]: Arrowhead utilizes strategic partnerships to generate non-dilutive capital. A disruption in these agreements or a failure to secure new collaborations could impact the company's ability to fund its wholly-owned programs, including REDEMPLO.
Intellectual Property and Patent Challenges [medium — regulatory]: The company's business depends on its ability to protect its intellectual property and proprietary TRiM platform. Challenges to its patents or the emergence of competing technologies could adversely affect its competitive advantage and market exclusivity.

Industry Context

The biopharmaceutical industry, particularly in the RNAi therapeutic space, is characterized by rapid innovation and significant investment. Companies are focused on developing novel delivery mechanisms and targeting previously 'undruggable' diseases. Arrowhead operates in a competitive landscape with both large pharmaceutical players and emerging biotech firms vying for market share and scientific advancement.

Regulatory Implications

Arrowhead's business is highly dependent on navigating the complex regulatory pathways of the FDA and other global health authorities. Successful drug development, rigorous clinical trials, and adherence to stringent manufacturing and marketing regulations are paramount. Any misstep in the regulatory process, from approval to post-market surveillance, can have severe financial and reputational consequences.

What Investors Should Do

Monitor REDEMPLO's sHTG Phase 3 trial results and the 2026 supplemental NDA filing.
Evaluate the performance and market penetration of REDEMPLO in the FCS indication.
Track progress of key pipeline assets like Zodasiran (ARO-ANG3) and ARO-DIMER-PA.
Assess the impact of strategic partnerships on non-dilutive capital and pipeline advancement.

Key Dates

2025-01-01: FDA Approval and Commercial Launch of REDEMPLO (plozasiran) — Marks Arrowhead's first commercial product, a significant milestone for the company and a validation of its TRiM platform.
2026-01-01: Planned Supplemental NDA Filing for REDEMPLO in sHTG — Represents a potential expansion of REDEMPLO's market reach into a higher prevalence disease, contingent on successful Phase 3 studies.

Glossary

RNA interference (RNAi): A natural biological process in cells that inhibits the expression of specific genes, thereby affecting protein production. (This is the core mechanism by which Arrowhead's therapies work to silence disease-causing genes.)
TRiM platform: Arrowhead's proprietary technology for delivering RNAi therapeutics to specific tissues in the body. (The platform's ability to achieve tissue-specific delivery is crucial for the efficacy and safety of their drug candidates.)
Familial Chylomicronemia Syndrome (FCS): A rare genetic disorder characterized by extremely high levels of triglycerides in the blood. (FCS is the indication for which REDEMPLO received its first FDA approval and commercial launch.)
Severe hypertriglyceridemia (sHTG): A condition characterized by very high triglyceride levels, posing significant health risks. (This is a target indication for a supplemental NDA filing for REDEMPLO in 2026, representing a larger potential market.)
Non-dilutive capital: Funding obtained by a company that does not involve issuing new shares of stock, such as through licensing or collaboration agreements. (Arrowhead relies on these agreements to fund its wholly-owned programs without diluting existing shareholders.)
Supplemental NDA: An application submitted to the FDA to approve a supplement to an existing drug approval, often for a new indication or formulation. (Arrowhead plans to file a supplemental NDA for REDEMPLO for the sHTG indication.)

Year-Over-Year Comparison

This filing represents a significant shift for Arrowhead Pharmaceuticals, Inc. compared to previous periods, primarily due to the 2025 FDA approval and commercial launch of its first product, REDEMPLO. While specific year-over-year financial metrics like revenue and net income are not detailed in the provided text, the company's transition from a pure R&D focus to a commercial-stage entity is a major development. New risks related to commercialization and market adoption are now more prominent, alongside the ongoing risks associated with pipeline development and regulatory approvals.

Filing Stats: 4,253 words · 17 min read · ~14 pages · Grade level 16 · Accepted 2025-11-25 16:13:58

Key Financial Figures

$0.001 — ange on which registered Common Stock, $0.001 par value ARWR The Nasdaq Global Select

Filing Documents

arwr-20250930.htm (10-K) — 2328KB
projectauckland-licensecol.htm (EX-10.52) — 1015KB
subsidiarylisting-ex211.htm (EX-21.1) — 5KB
arwr-20250930xex231.htm (EX-23.1) — 3KB
arrowheadengagementlette.htm (EX-23.2) — 2KB
arwr-20250930xex311.htm (EX-31.1) — 9KB
arwr-20250930xex312.htm (EX-31.2) — 9KB
arwr-20250930xex321.htm (EX-32.1) — 4KB
arwr-20250930xex322.htm (EX-32.2) — 4KB
arrowheadengagementlette001.jpg (GRAPHIC) — 135KB
arrowheadengagementlette002.jpg (GRAPHIC) — 191KB
arrowheadengagementlette003.jpg (GRAPHIC) — 168KB
arrowheadengagementlette004.jpg (GRAPHIC) — 273KB
arwr-20250930_g1.jpg (GRAPHIC) — 152KB
arwr-20250930_g2.jpg (GRAPHIC) — 32KB
arwr-20250930_g3.jpg (GRAPHIC) — 176KB
arwr-20250930_g4.jpg (GRAPHIC) — 95KB
arwr-20250930_g5.jpg (GRAPHIC) — 121KB
arwr-20250930_g6.jpg (GRAPHIC) — 92KB
0000879407-25-000029.txt ( ) — 15403KB
arwr-20250930.xsd (EX-101.SCH) — 81KB
arwr-20250930_cal.xml (EX-101.CAL) — 119KB
arwr-20250930_def.xml (EX-101.DEF) — 401KB
arwr-20250930_lab.xml (EX-101.LAB) — 903KB
arwr-20250930_pre.xml (EX-101.PRE) — 697KB
arwr-20250930_htm.xml (XML) — 1639KB

BUSINESS

BUSINESS 1 ITEM 1A.

RISK FACTORS

RISK FACTORS 30 ITEM 1B. UNRESOLVED STAFF COMMENTS 59

CYBERSECURITY

ITEM 1C. CYBERSECURITY 59 ITEM 2.

PROPERTIES

PROPERTIES 60 ITEM 3.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 60 ITEM 4. MINE SAFETY DISCLOSURES 60 PART II ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 61 ITEM 6. RESERVED 62 ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 62 ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 72 ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 72 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 73 ITEM 9A.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 73 ITEM 9B. OTHER INFORMATION 74 ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 74 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE 74 ITEM 11.

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 74 ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 74 ITEM 13. CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTORS INDEPENDENCE 75 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 75 PART IV ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 75 ITEM 16. FORM 10-K SUMMARY 79 SIGNATURE INDEX TO FINANCIAL STATEMENTS AND SCHEDULES F- 1

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Annual Report on Form 10-K except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "might," "will," "expect," "believe," "anticipate," "goal," "endeavor," "strive," "intend," "plan," "project," "could," "estimate," "target," "might," "forecast," or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding our commercialization efforts for REDEMPLO; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding the amount and timing of future milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. The forward-looking statements included herein are based on current expectation

BUSINESS

ITEM 1. BUSINESS A. Overview The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. There are currently 18 Arrowhead discovered drug candidates in clinical trials ranging from early stage (Phase 1) to late stage (Phase 3). In addition, the company has a robust discovery stage pipeline which is capable of generating multiple new clinical candidates each year. The Company recently achieved a transformational milestone with its first commercial launch in 2025, when the U.S. Food and Drug Administration ("FDA") approved REDEMPLO (plozasiran) as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome ("FCS"). Additionally, phase 3 studies (SHASTA-3, SHASTA-4 and SHASTA-5) for severe hypertriglyceridemia ("sHTG") have been fully enrolled and the Company plans to file a supplemental NDA for this indication in 2026, pending successful completion of Phase 3 clinical studies. The Company has built a commercial organization to support marketing in FCS, a rare disease, and plans to progressively build its commercial capabilities to also support marketing in sHTG, a higher prevalence disease which will require a larger commercial footprint. The Company has entered into multiple license and collaboration agreements with leading biotech and pharmaceutical companies, including Sarepta Therapeutics, Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Glaxosmithkline Intellectual Property (No. 3) Limited and Novartis Pharma AG, for programs that the Company does not intend to commercialize independently. This approach aims to expand the reach of the Company's technology and provides a source of non-dilutive capital to support REDEMPLO and other wholly-owned programs through commercial stage. RNA Interfe

View Full Filing

View this 10-K filing on SEC EDGAR